Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322626837> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4322626837 endingPage "1323" @default.
- W4322626837 startingPage "1317" @default.
- W4322626837 abstract "Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver function. The albumin-bilirubin (ALBI) grade is a novel indicator for predicting liver function in patients with hepatic disease. This study aimed to investigate the relationship between ALBI grade and HCC patients' lenvatinib treatment duration.This is a retrospective cohort study of patients with HCC and Child-Pugh A treated with lenvatinib between April 2018 and December 2019. The baseline liver function was determined using the ALBI grade. The primary outcome was discontinuation owing to adverse events. The risk factors for discontinuation owing to adverse effects were analyzed using logistic regression.This investigation included 48 HCC patients. Patients with ALBI grade 2 had a significantly shorter time of discontinuation due to adverse events than those with grade 1 (p=0.036). However, the time of treatment failure did not differ between the groups. Multiple logistic regression analysis showed that ALBI grade 2 and non-use of antihypertensive drugs were independent factors for discontinuation due to adverse events [odds ratio (OR)=14.1, 95% confidence interval (CI)=1.46-135, p=0.022 and OR=5.48, 95% CI=1.13-23.9, p=0.024, respectively].The ALBI grades may be useful in predicting adverse events caused by lenvatinib in patients with HCC and Child-Pugh A." @default.
- W4322626837 created "2023-03-01" @default.
- W4322626837 creator A5009948922 @default.
- W4322626837 creator A5027526564 @default.
- W4322626837 creator A5050794257 @default.
- W4322626837 creator A5051979269 @default.
- W4322626837 creator A5059944980 @default.
- W4322626837 creator A5075539354 @default.
- W4322626837 creator A5086943950 @default.
- W4322626837 creator A5089317397 @default.
- W4322626837 creator A5089636709 @default.
- W4322626837 date "2023-02-28" @default.
- W4322626837 modified "2023-10-05" @default.
- W4322626837 title "ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma" @default.
- W4322626837 doi "https://doi.org/10.21873/anticanres.16279" @default.
- W4322626837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36854508" @default.
- W4322626837 hasPublicationYear "2023" @default.
- W4322626837 type Work @default.
- W4322626837 citedByCount "0" @default.
- W4322626837 crossrefType "journal-article" @default.
- W4322626837 hasAuthorship W4322626837A5009948922 @default.
- W4322626837 hasAuthorship W4322626837A5027526564 @default.
- W4322626837 hasAuthorship W4322626837A5050794257 @default.
- W4322626837 hasAuthorship W4322626837A5051979269 @default.
- W4322626837 hasAuthorship W4322626837A5059944980 @default.
- W4322626837 hasAuthorship W4322626837A5075539354 @default.
- W4322626837 hasAuthorship W4322626837A5086943950 @default.
- W4322626837 hasAuthorship W4322626837A5089317397 @default.
- W4322626837 hasAuthorship W4322626837A5089636709 @default.
- W4322626837 hasConcept C126322002 @default.
- W4322626837 hasConcept C143998085 @default.
- W4322626837 hasConcept C156957248 @default.
- W4322626837 hasConcept C197934379 @default.
- W4322626837 hasConcept C2776264508 @default.
- W4322626837 hasConcept C2778019345 @default.
- W4322626837 hasConcept C2778695046 @default.
- W4322626837 hasConcept C2778715236 @default.
- W4322626837 hasConcept C2992208098 @default.
- W4322626837 hasConcept C71924100 @default.
- W4322626837 hasConcept C90924648 @default.
- W4322626837 hasConceptScore W4322626837C126322002 @default.
- W4322626837 hasConceptScore W4322626837C143998085 @default.
- W4322626837 hasConceptScore W4322626837C156957248 @default.
- W4322626837 hasConceptScore W4322626837C197934379 @default.
- W4322626837 hasConceptScore W4322626837C2776264508 @default.
- W4322626837 hasConceptScore W4322626837C2778019345 @default.
- W4322626837 hasConceptScore W4322626837C2778695046 @default.
- W4322626837 hasConceptScore W4322626837C2778715236 @default.
- W4322626837 hasConceptScore W4322626837C2992208098 @default.
- W4322626837 hasConceptScore W4322626837C71924100 @default.
- W4322626837 hasConceptScore W4322626837C90924648 @default.
- W4322626837 hasIssue "3" @default.
- W4322626837 hasLocation W43226268371 @default.
- W4322626837 hasLocation W43226268372 @default.
- W4322626837 hasOpenAccess W4322626837 @default.
- W4322626837 hasPrimaryLocation W43226268371 @default.
- W4322626837 hasRelatedWork W14759935 @default.
- W4322626837 hasRelatedWork W2466156289 @default.
- W4322626837 hasRelatedWork W2791311396 @default.
- W4322626837 hasRelatedWork W2806906789 @default.
- W4322626837 hasRelatedWork W2943140820 @default.
- W4322626837 hasRelatedWork W3012194080 @default.
- W4322626837 hasRelatedWork W4226048327 @default.
- W4322626837 hasRelatedWork W4322626837 @default.
- W4322626837 hasRelatedWork W4324130400 @default.
- W4322626837 hasRelatedWork W4360619981 @default.
- W4322626837 hasVolume "43" @default.
- W4322626837 isParatext "false" @default.
- W4322626837 isRetracted "false" @default.
- W4322626837 workType "article" @default.